File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Comparison of real-time PCR assays for monitoring serum HBV DNA levels during antiviral therapy

TitleComparison of real-time PCR assays for monitoring serum HBV DNA levels during antiviral therapy
Authors
Issue Date2006
PublisherBlackwell Publishing Asia.
Citation
The 2006 Shanghai-Hong Kong International Liver Congress, Shanghai, China, 25-28 March 2006. In Journal of Gastroenterology and Hepatology, v. 21 suppl. s2, p. A140, abstract no. 219 How to Cite?
AbstractINTRODUCTION & AIM: Monitoring of serum HBV DNA levels is established as a gold standard to assess antiviral potency. However, currently used commercial assays have limitations with respect to sensitivity and dynamic range of quantification. The objective of the present study was to compare two real-time PCR based assays, the RealARTTM and Molecular Beacons assays, with the Digene Hybrid Capture II assay (ultrasensitive) in patients undergoing antiviral therapy. METHODS: A total of 224 serum samples from 14 hepatitis B e antigen-positive chronic hepatitis B patients; 9 on adefovir dipivoxil plus emtricitabine combination therapy and 5 on adefovir dipivoxil monotherapy, were tested for HBV DNA using the three assays. RESULTS: The RealARTTM and Digene Hybrid assays were significantly related (r = 0.94, p < 0.001). The Molecular Beacons and Digene assays were also correlated (r = 0.79, p < 0.001). There was a good agreement between the RealARTTM and Digene assays. The mean difference was −1.05, as expected for good agreement, and 95% of the data were between +0.12 and −2.19 after logarithmic transformation. The RealARTTM assay diverged from the Digene assay in a range of 2 orders of magnitude. On the other hand, the mean difference was −1.73 when Molecular Beacons was compared with the Digene assay and the limits of agreement were +0.33 and −3.79 respectively. Molecular Beacons differed from the Digene assay by 4 orders of magnitude.The RealARTTM Digene and Molecular Beacons assays revealed coefficients of variation of 5.33%, 6.03% and 6.47%, respectively. CONCLUSION: The RealARTTM assay has a better correlation with the Digene assay and can be used effectively to monitor patients with high serum HBV DNA levels. It is also effective in the monitoring of patients whose serum HBV DNA levels have been suppressed to undetectable level by other commercial assays after antiviral therapy.
DescriptionThis journal suppl. entitled: Abstract and Proceeding of the Shanghai-Hong Kong International Liver Congress
Poster Session - Hepatitis (Diagnosis/Pathogenesis/Therapy)
Persistent Identifierhttp://hdl.handle.net/10722/108077
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190

 

DC FieldValueLanguage
dc.contributor.authorZhang, HYen_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorWong, Aen_HK
dc.contributor.authorLee, NPen_HK
dc.contributor.authorLeung, Nen_HK
dc.contributor.authorLuk, JMen_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2010-09-26T00:24:30Z-
dc.date.available2010-09-26T00:24:30Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 2006 Shanghai-Hong Kong International Liver Congress, Shanghai, China, 25-28 March 2006. In Journal of Gastroenterology and Hepatology, v. 21 suppl. s2, p. A140, abstract no. 219en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/108077-
dc.descriptionThis journal suppl. entitled: Abstract and Proceeding of the Shanghai-Hong Kong International Liver Congress-
dc.descriptionPoster Session - Hepatitis (Diagnosis/Pathogenesis/Therapy)-
dc.description.abstractINTRODUCTION & AIM: Monitoring of serum HBV DNA levels is established as a gold standard to assess antiviral potency. However, currently used commercial assays have limitations with respect to sensitivity and dynamic range of quantification. The objective of the present study was to compare two real-time PCR based assays, the RealARTTM and Molecular Beacons assays, with the Digene Hybrid Capture II assay (ultrasensitive) in patients undergoing antiviral therapy. METHODS: A total of 224 serum samples from 14 hepatitis B e antigen-positive chronic hepatitis B patients; 9 on adefovir dipivoxil plus emtricitabine combination therapy and 5 on adefovir dipivoxil monotherapy, were tested for HBV DNA using the three assays. RESULTS: The RealARTTM and Digene Hybrid assays were significantly related (r = 0.94, p < 0.001). The Molecular Beacons and Digene assays were also correlated (r = 0.79, p < 0.001). There was a good agreement between the RealARTTM and Digene assays. The mean difference was −1.05, as expected for good agreement, and 95% of the data were between +0.12 and −2.19 after logarithmic transformation. The RealARTTM assay diverged from the Digene assay in a range of 2 orders of magnitude. On the other hand, the mean difference was −1.73 when Molecular Beacons was compared with the Digene assay and the limits of agreement were +0.33 and −3.79 respectively. Molecular Beacons differed from the Digene assay by 4 orders of magnitude.The RealARTTM Digene and Molecular Beacons assays revealed coefficients of variation of 5.33%, 6.03% and 6.47%, respectively. CONCLUSION: The RealARTTM assay has a better correlation with the Digene assay and can be used effectively to monitor patients with high serum HBV DNA levels. It is also effective in the monitoring of patients whose serum HBV DNA levels have been suppressed to undetectable level by other commercial assays after antiviral therapy.-
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia.en_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.titleComparison of real-time PCR assays for monitoring serum HBV DNA levels during antiviral therapyen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=21&issue=2&spage=A140&epage=&date=2006&atitle=Comparison+of+Real-Time+PCR+Assays+for+monitoring+Serum+HBV+DNA+Levels+During+Antiviral+Therapyen_HK
dc.identifier.emailZhang, HY: hying64@hku.hken_HK
dc.identifier.emailHui, CK: ckh23@cam.ac.uken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.emailLau, GKK: gkklau@netvigator.comen_HK
dc.identifier.authorityLuk, JMC=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1746.2006.04409.x-
dc.identifier.hkuros120340en_HK
dc.identifier.volume21en_HK
dc.identifier.issuesuppl. s2en_HK
dc.identifier.spageA140, abstract no. 219en_HK
dc.identifier.epageA140, abstract no. 219-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats